<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425100</url>
  </required_header>
  <id_info>
    <org_study_id>A0221007</org_study_id>
    <nct_id>NCT00425100</nct_id>
  </id_info>
  <brief_title>A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients</brief_title>
  <official_title>A 12-Week, Multicenter, Open-Label, Single-Arm Study To Evaluate The Effects Of Fesoterodine On Treatment Satisfaction And Symptom Relief In Overactive Bladder Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB)
      symptom relief in OAB patients who were dissatisfied with their prior therapy with
      tolterodine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Number of Micturition Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Number of Urgency Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Satisfaction With Current Overactive Bladder (OAB) Treatment</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Micturitions Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Urgency Episodes Per 24 Hours</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rating on the Urinary Sensation Scale</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Bladder Condition (PPBC) Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Bladder Condition (PPBC) Score at Week 12 Relative to Baseline (Categorical Change)</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency Perception Scale (UPS)</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency Perception Scale (UPS) at Week 12 Relative to Baseline (Categorical Change)</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Concern Domain</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Coping Domain</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Sleep Domain</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Social Interaction Domain</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q) - Total Health Related Quality of Life (HRQL) Scale</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q) - Symptom Bother Scale</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Satisfaction With OAB Control&quot; Module of Overactive Bladder (OAB) Treatment Satisfaction Questionnaire (TSQ) (OAB-S)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum Rating on the Urinary Sensation Scale</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treated Subjects Reporting Satisfaction With Their Current OAB Treatment (Supportive Analysis)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">516</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Open Label-fesoterodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment study arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine fumarate</intervention_name>
    <description>12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.</description>
    <arm_group_label>Open Label-fesoterodine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OAB patients who present with OAB symptoms(≥8 micturitions and ≥3 urgency episodes per
             24 h documented in the baseline bladder diary)

          -  OAB patients dissatisfied with their prior therapy with tolterodine

        Exclusion Criteria:

          -  Patients with any contraindication to fesoterodine usage, e.g., urinary retention,
             gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to
             the drug or its ingredients.

          -  Patients with significant hepatic and renal disease or other significant unstable
             diseases.

          -  OAB symptoms caused by neurological conditions, known pathologies of urinary tract,
             etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orangevale</city>
        <state>California</state>
        <zip>95662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shrevport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Westampton</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethany</city>
        <state>Oklahoma</state>
        <zip>73008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jette</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <zip>B-2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alajuela Centro</city>
        <state>Alajuela</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno-Bohunice</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>152 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muelheim a.d. Ruhr</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyunggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jeonnam</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malacky</city>
        <zip>901 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Skalica</city>
        <zip>909 82</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Odessa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221007&amp;StudyName=A%20Clinical%20Trial%20To%20Assess%20Fesoterodine%20On%20Treatment%20Satisfaction%20And%20Symptom%20Improvement%20In%20Overactive%20Bladder%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <results_first_submitted>October 10, 2008</results_first_submitted>
  <results_first_submitted_qc>January 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2009</results_first_posted>
  <last_update_submitted>February 24, 2009</last_update_submitted>
  <last_update_submitted_qc>February 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 59 centers (Belgium 5 centers, Costa Rica 2, Czech Republic 4, Germany 7, Republic of Korea 6, Poland 2, Slovakia 5, Ukraine 5, United States 23). Two centers in the United States did not randomize subjects.</recruitment_details>
      <pre_assignment_details>595 subjects were screened. Responses to a 5-day bladder diary (during a 2-week screening period) identified subjects who met all other entry criteria for enrollment for study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label-fesoterodine</title>
          <description>All enrolled subjects were treated with fesoterodine 4 mg once daily (QD) for 4 weeks followed by either 4 mg QD or 8 mg QD for the remaining 8 weeks of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="516"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="463"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label-fesoterodine</title>
          <description>All enrolled subjects were treated with fesoterodine 4 mg once daily (QD) for 4 weeks followed by either 4 mg QD or 8 mg QD for the remaining 8 weeks of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="516"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Micturition Episodes Per 24 Hours</title>
        <description>The mean number of micturitions per 24 hours is calculated as the total number of micturitions divided by the total number of diary days collected at that visit.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (last observation carried forward (LOCF)). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Micturition Episodes Per 24 Hours</title>
          <description>The mean number of micturitions per 24 hours is calculated as the total number of micturitions divided by the total number of diary days collected at that visit.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (last observation carried forward (LOCF)). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of micturition episodes per 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="3.9"/>
                    <measurement group_id="O2" value="9.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Open-label study with statistical comparison between baseline and Week 12. Null hypothesis: The mean change from baseline in number of micturition episodes per 24 hours at Week 12 is equal to 0. The sample size was based on a statistical power for each of the three individual diary endpoints of .95 which would yield an overall power of 85%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>All paired t-tests were performed with a two-sided test at significance level of 5%. Efficacy was claimed only when all 3 primary diary endpoints demonstrated statistical significance in change from baseline to Week 12.</p_value_desc>
            <method>2-sided paired t-test</method>
            <method_desc>paired t-test comparing baseline with post-baseline values</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours</title>
        <description>The mean number of UUI episodes per 24 hours is calculated as the total number of micturitions with Bladder Sensation Scale (BSS) = 5 divided by the total number of diary days collected at that visit. BSS: 5 point scale measuring need to urinate from 1=no urgency to 5=unable to hold; leak urine.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (last observation carried forward (LOCF)). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment. Restricted to subjects with UUI at baseline &gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours</title>
          <description>The mean number of UUI episodes per 24 hours is calculated as the total number of micturitions with Bladder Sensation Scale (BSS) = 5 divided by the total number of diary days collected at that visit. BSS: 5 point scale measuring need to urinate from 1=no urgency to 5=unable to hold; leak urine.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (last observation carried forward (LOCF)). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment. Restricted to subjects with UUI at baseline &gt;0.</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.8"/>
                    <measurement group_id="O2" value="0.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Open-label study with statistical comparison between baseline and Week 12. Null hypothesis: The mean change from baseline in number of urgency urinary incontinence per 24 hours is equal to 0. The sample size was based on a statistical power for each of the three individual diary endpoints of .95 which would yield an overall power of 85%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>All paired t-tests were performed with a two-sided test at significance level of 5%. Efficacy was claimed only when all 3 primary diary endpoints demonstrated statistical significance in change from baseline to Week 12.</p_value_desc>
            <method>2-sided paired t-test</method>
            <method_desc>paired t-test comparing baseline with post-baseline values</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Urgency Episodes Per 24 Hours</title>
        <description>The mean number of urgency episodes per 24 hours is calculated as the total number of micturitions with Bladder Sensation Scale (BSS) &gt;= 3 divided by the total number of diary days collected at that visit. BSS: 5 point scale measuring need to urinate from 1=no urgency to 5=unable to hold; leak urine.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (last observation carried forward (LOCF)).The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Urgency Episodes Per 24 Hours</title>
          <description>The mean number of urgency episodes per 24 hours is calculated as the total number of micturitions with Bladder Sensation Scale (BSS) &gt;= 3 divided by the total number of diary days collected at that visit. BSS: 5 point scale measuring need to urinate from 1=no urgency to 5=unable to hold; leak urine.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (last observation carried forward (LOCF)).The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="4.5"/>
                    <measurement group_id="O2" value="5.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Open-label study with statistical comparison between baseline and Week 12. Null hypothesis: The mean change from baseline in number of urgency episodes per 24 hours is equal to 0. The sample size was based on a statistical power for each of the three individual diary endpoints of .95 which would yield an overall power of 85%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>All paired t-tests were performed with a two-sided test at significance level of 5%. Efficacy was claimed only when all 3 primary diary endpoints demonstrated statistical significance in change from baseline to Week 12.</p_value_desc>
            <method>2-sided paired t-test</method>
            <method_desc>paired t-test comparing baseline with post-baseline values</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>-4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Satisfaction With Current Overactive Bladder (OAB) Treatment</title>
        <description>Number of Participants who responded satisfied = (very satisfied or somewhat satisfied) and dissatisfied = (somewhat dissatisfied or very dissatisfied) to the treatment satisfaction question.</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing value at Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Satisfaction With Current Overactive Bladder (OAB) Treatment</title>
          <description>Number of Participants who responded satisfied = (very satisfied or somewhat satisfied) and dissatisfied = (somewhat dissatisfied or very dissatisfied) to the treatment satisfaction question.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing value at Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfied (very satisfied or somewhat satisfied)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither dissatisfied nor satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied (somewhat or very dissatisfied)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Micturitions Per 24 Hours</title>
        <description>Nocturnal micturitions (synonymous with the term “nighttime micturitions”) were those recorded in the bedtime section of the bladder diary.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Micturitions Per 24 Hours</title>
          <description>Nocturnal micturitions (synonymous with the term “nighttime micturitions”) were those recorded in the bedtime section of the bladder diary.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>number of nocturnal micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.6"/>
                    <measurement group_id="O2" value="1.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2 sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Urgency Episodes Per 24 Hours</title>
        <description>Severe urgency episodes defined as Urinary Sensation Scale (USS) rating ≥4. Subjects rated the feeling of urgency associated with each micturition episode using USS provided in the bladder diary. Scale ranges from 1=no feeling of urgency to 5=unable to hold; leak urine; decrease indicates an improvement with respect to urgency symptoms.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with baseline severe urgency episodes &gt;0 and non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Severe Urgency Episodes Per 24 Hours</title>
          <description>Severe urgency episodes defined as Urinary Sensation Scale (USS) rating ≥4. Subjects rated the feeling of urgency associated with each micturition episode using USS provided in the bladder diary. Scale ranges from 1=no feeling of urgency to 5=unable to hold; leak urine; decrease indicates an improvement with respect to urgency symptoms.</description>
          <population>Subjects in the Full Analysis Set (FAS) with baseline severe urgency episodes &gt;0 and non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
                <count group_id="O2" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="4.4"/>
                    <measurement group_id="O2" value="1.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rating on the Urinary Sensation Scale</title>
        <description>The mean rating was calculated as the sum of rating scores on the Urinary Sensation Scale divided by the total number of micturitions with non-missing rating at that visit. The scale ranges from 1 “no feeling of urgency” to 5 “unable to hold; leak urine.”</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Rating on the Urinary Sensation Scale</title>
          <description>The mean rating was calculated as the sum of rating scores on the Urinary Sensation Scale divided by the total number of micturitions with non-missing rating at that visit. The scale ranges from 1 “no feeling of urgency” to 5 “unable to hold; leak urine.”</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.6"/>
                    <measurement group_id="O2" value="2.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Bladder Condition (PPBC) Score</title>
        <description>The PPBC score ranges from 1 “no problems at all” to 6 “many severe problems.”</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Bladder Condition (PPBC) Score</title>
          <description>The PPBC score ranges from 1 “no problems at all” to 6 “many severe problems.”</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="487"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.7"/>
                    <measurement group_id="O2" value="3.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Bladder Condition (PPBC) Score at Week 12 Relative to Baseline (Categorical Change)</title>
        <description>Improvement: negative score change; No change: score change=0; Deterioration: positive score change</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Bladder Condition (PPBC) Score at Week 12 Relative to Baseline (Categorical Change)</title>
          <description>Improvement: negative score change; No change: score change=0; Deterioration: positive score change</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urgency Perception Scale (UPS)</title>
        <description>UPS scores range from 0 (“I am usually not able to hold urine”) to 2 (“I am usually able to finish what I am doing before going to the toilet [without leaking]”).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Urgency Perception Scale (UPS)</title>
          <description>UPS scores range from 0 (“I am usually not able to hold urine”) to 2 (“I am usually able to finish what I am doing before going to the toilet [without leaking]”).</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.5"/>
                    <measurement group_id="O2" value="1.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urgency Perception Scale (UPS) at Week 12 Relative to Baseline (Categorical Change)</title>
        <description>Improvement: positive score change; No improvement: zero or negative score change</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Urgency Perception Scale (UPS) at Week 12 Relative to Baseline (Categorical Change)</title>
          <description>Improvement: positive score change; No improvement: zero or negative score change</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Concern Domain</title>
        <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Concern Domain</title>
          <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="25.3"/>
                    <measurement group_id="O2" value="79.1" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>28.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.4</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Coping Domain</title>
        <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Coping Domain</title>
          <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="25.3"/>
                    <measurement group_id="O2" value="75.3" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>30.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.6</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Sleep Domain</title>
        <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Sleep Domain</title>
          <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="25.5"/>
                    <measurement group_id="O2" value="72.3" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>24.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.3</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Social Interaction Domain</title>
        <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Social Interaction Domain</title>
          <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="23.5"/>
                    <measurement group_id="O2" value="88.1" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>16.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.1</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q) - Total Health Related Quality of Life (HRQL) Scale</title>
        <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q) - Total Health Related Quality of Life (HRQL) Scale</title>
          <description>Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="21.8"/>
                    <measurement group_id="O2" value="78.3" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>26.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.8</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q) - Symptom Bother Scale</title>
        <description>Each item rated by subject on a Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent less favorable outcome.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q) - Symptom Bother Scale</title>
          <description>Each item rated by subject on a Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent less favorable outcome.</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12. The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4" spread="18.7"/>
                    <measurement group_id="O2" value="28.6" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-28.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.7</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>&quot;Satisfaction With OAB Control&quot; Module of Overactive Bladder (OAB) Treatment Satisfaction Questionnaire (TSQ) (OAB-S)</title>
        <description>Module coded on scale (1-very satisfied to 5-very dissatisfied). Coding reversed algorithmically &amp; results transformed: total score range 0-100. Higher final response value associated with better satisfaction. Satisfied on TSQ = very or somewhat satisfied; Not satisfied on TSQ =very or somewhat dissatisfied or neither dissatisfied nor satisfied.</description>
        <time_frame>Week 12</time_frame>
        <population>Population included subjects in FAS (described above) with non-missing values on OAB-S at Week 12, referred to in table below as All Subjects. Summary was presented for All Subjects and 2 subgroups, based on categorization for treatment satisfaction question used in primary endpoint assessing satisfaction.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>&quot;Satisfaction With OAB Control&quot; Module of Overactive Bladder (OAB) Treatment Satisfaction Questionnaire (TSQ) (OAB-S)</title>
          <description>Module coded on scale (1-very satisfied to 5-very dissatisfied). Coding reversed algorithmically &amp; results transformed: total score range 0-100. Higher final response value associated with better satisfaction. Satisfied on TSQ = very or somewhat satisfied; Not satisfied on TSQ =very or somewhat dissatisfied or neither dissatisfied nor satisfied.</description>
          <population>Population included subjects in FAS (described above) with non-missing values on OAB-S at Week 12, referred to in table below as All Subjects. Summary was presented for All Subjects and 2 subgroups, based on categorization for treatment satisfaction question used in primary endpoint assessing satisfaction.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Subjects (N=473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects satisfied on TSQ (n=377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects not satisfied on TSQ (n=96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum Rating on the Urinary Sensation Scale</title>
        <description>The sum rating per 24 hours was calculated as the mean rating score on the Urinary Sensation Scale multiplied by the mean number of micturitions per 24 hours at that visit. The scale ranges from 1 “no feeling of urgency” to 5 “unable to hold; leak urine.”</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Baseline</title>
          </group>
          <group group_id="O2">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Sum Rating on the Urinary Sensation Scale</title>
          <description>The sum rating per 24 hours was calculated as the mean rating score on the Urinary Sensation Scale multiplied by the mean number of micturitions per 24 hours at that visit. The scale ranges from 1 “no feeling of urgency” to 5 “unable to hold; leak urine.”</description>
          <population>Subjects in the Full Analysis Set (FAS) with non-missing numerical change from baseline to Week 12 (LOCF). The FAS included all subjects who took at least 1 dose of assigned study drug and contributed data to at least 1 baseline or post-baseline efficacy assessment.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="15.6"/>
                    <measurement group_id="O2" value="25.2" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between baseline and Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All paired t-tests were performed with a two-sided test at significance level of 5%.</p_value_desc>
            <method>2-sided paired t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-15.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.2</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treated Subjects Reporting Satisfaction With Their Current OAB Treatment (Supportive Analysis)</title>
        <description>Number of participants who responded satisfied = (very satisfied or somewhat satisfied) or dissatisfied = (somewhat dissatisfied or very dissatisfied) to the treatment satisfaction question at Week 12 in the safety set.</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in safety set included subjects who took at least one dose of study drug. Missing responses to the Treatment Satisfaction Question at Week 12 were imputed as not satisfied for calculating the most conservative treatment satisfaction.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Week 12</title>
          </group>
        </group_list>
        <measure>
          <title>Treated Subjects Reporting Satisfaction With Their Current OAB Treatment (Supportive Analysis)</title>
          <description>Number of participants who responded satisfied = (very satisfied or somewhat satisfied) or dissatisfied = (somewhat dissatisfied or very dissatisfied) to the treatment satisfaction question at Week 12 in the safety set.</description>
          <population>Subjects in safety set included subjects who took at least one dose of study drug. Missing responses to the Treatment Satisfaction Question at Week 12 were imputed as not satisfied for calculating the most conservative treatment satisfaction.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfied (very satisfied or somewhat satisfied)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Dissatisfied nor Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied (somewhat or very dissatisfied)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Response (imputed as dissatisfied)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

